Audit: QRS - Low-Dose Aspirin for Health & Longevity
Audit conducted on 22/10/2026 19:57 using AI4L / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 87 |
| Failed | 0 |
| N/A | 7 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All gates, tiers, protocol cells, markers and At-a-Glance statements trace to ER text (e.g., L447 ↔ ER L379; L619–674 ↔ ER L446–451). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious phrasing carried over, e.g., “Caution (theoretical)” (L574 ↔ ER L341), “No interaction found” (L568 ↔ ER L332). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening found; “Avoid taking before aspirin” (L566) and age-60 gate (L547) match ER L330, L354. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come from the ER avoid-list, interactions from the interaction bullets, risks from the Risks section. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs, trial names or brand names; “USPSTF” appears in the ER label (ER L380). |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No new attributions introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s measured, evidence-weighing tone. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert, data-based and neutral throughout. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents ER content; guideline position is attributed to USPSTF (L455–461). |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No clinical advice beyond ER-stated labels and guideline positions. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Information is presented, not advised. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No direct reader address. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain-language glosses used where helpful (e.g., L542, L649); technical terms are ER labels. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Compact single-line items throughout. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No second-person address found. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framed for proactive, risk-aware adults weighing use. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol, monitoring cadence and qualitative checks assume a committed user. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not framed for a general, unengaged audience. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-Glance separates established-disease benefit from small net value in healthy people and late starters (L433). |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No “anti-aging” wording. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | “oral medication” used in the lede (L433); no colloquial route or adverse-event wording. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | All fixed headings, gate headings, tier labels and column headers unchanged (L440, L477, L519, L585, L604, L701, L539, L552, L608–610). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All template spans present; marker_# and qualitative_item_# expanded to 7 and 6 rows. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff against the template shows changes only inside variable spans and metadata. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | 🟢 | Empty ER sub-sections (Speculative risks) are hidden per 13.5; no empty-state phrasing needed. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels “Standard dose”, “Guideline approach (USPSTF)”, “Formulation” and interaction labels match ER bold labels. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels match ER; example lists trimmed only, with at least one example kept. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators. |
| 4.5 | The QRS is designed to render on one A4 page: every section is condensed to the shortest form the other checklist items allow, not extended onto a second page. | 🟢 | Items condensed; the long content is required gates, labels and markers. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment is the first element after <!doctype html> (L2–14). |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML delimited by — lines (L3, L13). |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Inside an HTML comment; not surfaced. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed; only duration “00:00” quoted (contains a colon). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: low_dose_aspirin_2026-1022-1349_Opus_ER.md (L4). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.10.18 matches QRS.md (L5). |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-1022-1929 (L6). |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus (L7). |
| 5.9 | The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT) | 🟢 | “Opus” is the full name without the version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5.5 (L8). |
| 5.11 | The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y) | 🟢 | “Opus 5.5” follows the naming rule. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename matches the file name (L9). |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed; quoting only where required. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Title “Low-Dose Aspirin for Health & Longevity - Quick Reference Sheet” (L22). |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | header_topic matches canonical_topic with & (L417). |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 10/22/2026 matches qrs_creation_date 2026-1022-1929 (L421). |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Opus 5.5 (L425). |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | No extra header content. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens with “an over-the-counter oral medication … used to prevent blood clots” (L433). |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER Conclusion (ER L480–484): established disease, healthy people, bowel cancer, late starters. |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 67 words. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each sentence maps to ER Conclusion L480–482 and Age modifier ER L215. |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms or specialist terms. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trials cited. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | From ER “Populations who should avoid” (ER L347–354). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 6 ER avoid-populations listed (L542–547). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Each item is an <li>. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Reye’s rationale and USPSTF attribution stripped; key facts only. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Threshold “below 10 mL/minute”, example disorders and trimester window preserved (L544–546). |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation in contraindications. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section populated; ER names avoid-populations. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | From ER interaction bullets (ER L314–345). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All 21 ER interactions listed (L555–575); none duplicates a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each item is an <li>. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Rationale, citations and study details stripped; label plus severity only. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drugs and qualifiers kept, e.g., “three or more drinks daily” (L570), “with high-dose oral corticosteroids” (L562). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation in interactions. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section populated; ER names interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells from ER Therapeutic Protocol (ER L379, L380, L389). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, USPSTF guideline approach and formulation are core actionable aspects. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER provides three or more actionable aspects. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All used label/value/sub fields filled with ER-derived content. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Cardiovascular, platelet and cancer time-to-effect from ER L420, L387, L400. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered cardiovascular (High), platelet inhibition (mechanism of the High benefit), cancer (Low). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER provides three time-to-effect aspects. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All three sets filled with ER-derived content. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | From ER Expected Benefits headings. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four tier variables present. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Heading-level facts only. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | Medium has no ER items and its span is display: none (L524). |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | From ER Potential Risks & Side Effects headings. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four tier variables present. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Heading-level facts only. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | Speculative has no ER items and its span is display: none (L596). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | From ER Monitoring table (ER L444–452). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 7 ER biomarkers listed (L614–690). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Cadence from ER L442 (L695). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | From ER qualitative markers (ER L454–461). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 6 qualitative markers listed (L704–719). |
Issues 22/10/2026 19:57
Pass rate 100.00%. No issues found.
Issues 22/10/2026 19:56
- 4.5 — Untrimmed example lists: Contraindications (line 544) keeps three examples “(such as hemophilia, liver disease, vitamin K deficiency)” and Key Interactions (line 574) keeps “(garlic, curcumin, nattokinase, a clot-dissolving soybean enzyme)”; both lists could be trimmed under 8.5 / 9.5 without breaking another item.
Fixes 22/10/2026 19:56
- 4.5 — Trimmed example lists: Shortened the bleeding-disorder examples from “(such as hemophilia, liver disease, vitamin K deficiency)” to “(such as hemophilia, liver disease)” and the additive antiplatelet supplements from “(garlic, curcumin, nattokinase, a clot-dissolving soybean enzyme)” to “(garlic, curcumin)”.
Issues 22/10/2026 19:49
- 2.2 — Missing space after semicolon: The [risks_low] list at line 594 reads “Aspirin-triggered asthma flares;higher death rate when started after 70”, with no space after the semicolon.
Fixes 22/10/2026 19:49
- 2.2 — Missing space after semicolon: Changed “asthma flares;higher death rate” to “asthma flares; higher death rate” in [risks_low].
Issues 22/10/2026 19:46
- 2.7 — Unnecessary jargon in tiers: benefits_high (line 522) uses “ischemic strokes” and “first unprovoked clot” although the ER provides the plain terms “clot-related” and “unexplained”; risks_low (line 594) uses “Aspirin-exacerbated respiratory disease”, which the ER describes plainly as asthma flaring after aspirin.
Fixes 22/10/2026 19:46
- 2.7 — Plain terms in tiers: In benefits_high, changed “ischemic strokes” to “clot-related strokes” and “first unprovoked clot” to “first unexplained clot”; in risks_low, changed “Aspirin-exacerbated respiratory disease” to “Aspirin-triggered asthma flares”, all wording supported by the ER.
Issues 22/10/2026 19:42
- 4.5 — Time subs repeat values: time_1_sub “Appear within the first years of use” (line 489) restates time_1_value “First years”, and time_3_sub “Emerged only after 3–5 years or more” (line 511) restates time_3_value “3–5+ years”.
Fixes 22/10/2026 19:42
- 4.5 — Time subs repeat values: Replaced time_1_sub “Appear within the first years of use” with “Of daily use” and time_3_sub “Emerged only after 3–5 years or more” with “Of continuous use; favors midlife starts” (ER: at least 5 years of continuous use; favoring midlife starts).
Issues 22/10/2026 19:36
- 2.7 — Unglossed acronyms in contraindications: The contraindication items use “NSAIDs” (line 542) and “GFR” (line 545) as bare acronyms outside any ER label, although the ER glosses both (“the ibuprofen-type class”; “the kidneys’ filtering rate”).
Fixes 22/10/2026 19:36
- 2.7 — Glossed contraindication acronyms: Changed “Allergy to NSAIDs” to “Allergy to NSAIDs (the ibuprofen-type class)” and “GFR below 10 mL/minute” to “kidney filtering rate below 10 mL/minute”, using the ER’s own glosses.
Issues 22/10/2026 19:34
- 1.3 — Benefit size qualifier dropped: At a Glance (QRS line 433) reads “fewer first heart attacks and strokes come with a matching rise in serious bleeding”, omitting the ER Conclusion’s “small” (ER line 480) and so strengthening the benefit claim.
- 4.5 — Untrimmed interaction example lists: Key Interactions keep full example lists that 9.5 allows to be trimmed: “Anticoagulants (warfarin, apixaban, rivaroxaban, heparin)” (line 555) and the SSRI list “sertraline, fluoxetine, escitalopram” (line 557).
Fixes 22/10/2026 19:34
- 1.3 — Benefit size qualifier restored: Changed At a Glance from “fewer first heart attacks and strokes come with a matching rise” to “a small drop in first heart attacks and strokes comes with a matching rise”, matching the ER Conclusion.
- 4.5 — Interaction example lists trimmed: Shortened “Anticoagulants (warfarin, apixaban, rivaroxaban, heparin)” to “(warfarin, apixaban)” and the SSRI examples to “sertraline, fluoxetine”, keeping the ER’s own words.